Conversely, CYP1B1 inhibition has been shown to lower blood pressure and mitigate endothelial and renal dysfunction, as well as fibrosis, while simultaneously reducing ROS production (Gangadhariah et al., 2017; Jennings et al., 2014). Here, CYP1B1 is linked to Abnormal renal physiology.